



PRESS RELEASE

Issued 14 January 2010

**GLYCOMAR'S SEARCH FOR NEW DRUGS FROM THE MARINE ENVIRONMENT  
ADVANCES WITH FILING OF FOUR PATENTS**

GlycoMar Limited is pleased to announce the filing of four US patent applications, which mark an important step forward in its drug discovery programme. Four new composition of matter patent applications have been jointly filed with Verona Pharma plc for products that have been discovered as a result of our collaborative research programme. These novel products have been identified from a number of marine organisms and have shown significant anti-inflammatory activity with clinical potential.

The compounds are produced by GlycoMar from marine organisms including starfish, sea squirts, and marine worms. GlycoMar has been working with Verona Pharma since November 2006 to carry out evaluation and testing of a wide range of potential novel anti-inflammatory polysaccharides (NAIPs). The goal of GlycoMar's collaboration with Verona Pharma is to find a suitable candidate for clinical proof of concept studies in man. The companies have expectations that the project will provide novel treatments for respiratory conditions such as asthma and hay fever and for other diseases in which inflammation has a substantial role.

GlycoMar is a privately held marine biotechnology company uniquely specialising in the discovery of novel sugar-based molecules from marine organisms, from its base at the European Centre for Marine Biotechnology, near Oban, Scotland. The Company is discovering and developing these molecules for a number of markets, with products in the pipeline for pharmaceutical, nutraceutical and cosmeceutical applications.

Founder and managing Director of GlycoMar, Dr. Charlie Bavington, said 'The filing of patent applications is an important step in the drug discovery process. These patents will provide validation of GlycoMar's approach and collaboration with Verona Pharma, adding value to this discovery programme, which we will actively promote over the next 12-18 months.'

Ends

Notes to newsdesks:

For further information on GlycoMar visit [www.glycomar.com](http://www.glycomar.com)

For further information on Verona Pharma Plc visit [www.veronapharma.com](http://www.veronapharma.com)

For further information contact:

Dr Charlie Bavington, GlycoMar Ltd

T: 01631 559370

M: 07833 108875

E: [charlie@glycomar.com](mailto:charlie@glycomar.com)

Twitter: [@cbav](https://twitter.com/cbav)